Kenneth B. Lee, General Partner
Ken is former co-head of the International Life Science Practice at Ernst & Young; He is currently Chairman of Inspire Pharmaceuticals, and a director of OSI Pharmaceuticals, Pozen and Maxygen. More...

Douglas Reed, MD, General Partner
Douglas Reed, M.D. joined Hatteras Venture Partners as a General Partner in early 2007. Prior to Hatteras, Doug had 14 years of venture investing experience with two healthcare-focused funds, Vector Fund Management and S.R. One. More...

Clay B. Thorp, General Partner
Clay B. Thorp is an entrepreneur turned venture capitalist. Since 1995, Clay has co-founded four companies in the life science arena and co-founded Hatteras in 2001 with the launch of seed-stage Hatteras Venture Partners I, L.P. (HVP I). More...

John Crumpler, General Partner
John is a co-founder of Hatteras. Formerly a successful software entrepreneur, he was founder and CEO of E-Comm, Inc. In addition to serving on the board of Clinipace, he is responsible for strategy, administration, and operations of Hatteras Venture Partners. More...

Robert Morff, PhD, Venture Partner
Bob has deep experience in medical devices and diagnostics product and business development. Having already served as interim CEO of Pathfinder, he is now a director there. Bob also serves as a director at Histosonics. More...

Dana M. Fowlkes, MD PhD, Venture Partner
Dana is a general partner of HVP II and a venture partner with HVP III. He was co-founder and former CEO of Novalon, co-founder of Merlin and Cadus, and a former faculty member in the Deparment of Pathology at UNC.

Michael Dial, PhD, Analyst
Prior to joining Hatteras, Mike was a Vice President in Silicon Valley Bank's Corporate Finance Group where he focused on emerging life science companies. More...

Scientific Advisory Board
Hatteras has an outstanding scientific advisory board chaired by Herb Boyer, the founder of Genentech, and composed of leading scientists in their respective fields:

• Herb Boyer, Ph.D., Co-Founder of Genentech, Professor Emeritus of Biochemistry and Biophysics, University of California, San Francisco
• James Powell, M.D., pathologist, founder of LabCorp and Tripath
• Charlie Sanders, M.D., cardiologist, former CEO of Glaxo and former Head of Massachusetts General Hospital
• David King, CEO of LabCorp
• Arnold Levine, Ph.D., Professor of Systems Biology, Institute for Advanced Study, former President and CEO of Rockefeller University
• Beat Merz, Ph.D., medical device expert, Partner at Ares Life Sciences, Investment Advisor at Trigon Medical, Director of Broncus
• Kazumi Shiosaki, Ph.D., Managing Director, MPM Capital, former SVP of Drug Discovery, Millennium Pharmaceuticals
• Thomas Deuel, M.D., discoverer of PDGF, cancer biology expert, member of Institute of Medicine at the National Academy of Sciences
• Martin J. Murphy, Jr., M.D., peer-reviewed scientist, professor, editor and consultant, convener of the CEO Roundtable on Cancer, founder and former CEO of the Hipple Cancer Research Center